Loading…
Relmada Therapeutics, Inc. is projected to rise to $8.65 by 2027, a +35% move from its current price of $6.41. RLMD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $6.23 | $6.42 | $6.60 | +0.08% |
| Jul 14 | $6.16 | $6.42 | $6.69 | +0.17% |
| Jul 15 | $6.11 | $6.43 | $6.76 | +0.25% |
| Jul 16 | $6.07 | $6.43 | $6.81 | +0.34% |
| Jul 17 | $6.03 | $6.44 | $6.87 | +0.42% |
| Jul 18 | $6.00 | $6.44 | $6.92 | +0.50% |
| Jul 19 | $5.97 | $6.45 | $6.96 | +0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.97 | $6.45 | $6.96 | +0.59% |
| Week 2 | $5.82 | $6.49 | $7.23 | +1.18% |
| Week 3 | $5.71 | $6.52 | $7.45 | +1.77% |
| Week 4 | $5.63 | $6.56 | $7.65 | +2.37% |
| Week 5 | $5.56 | $6.60 | $7.83 | +2.97% |
| Week 6 | $5.50 | $6.64 | $8.01 | +3.58% |
| Week 7 | $5.45 | $6.68 | $8.18 | +4.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD is the stock ticker for Relmada Therapeutics, Inc. It is currently trading at $6.73. The asset carries a market capitalization of $705.91M and a rank of 2790. The overall price outlook is bullish over the longer horizon, with forecasts showing a rising average price path: 2026 avg $6.73, 2030 avg $14.71, 2040 avg $62.26, and 2050 avg $119.42, underscoring strong upside potential despite near-term uncertainty.
Max price projections rise along the curve, with 2030 max $22.56, 2040 max $113.91, and 2050 max $242.38, reinforcing the bullish longer-term thesis.
A major floor 30.9% below — a decisive break under it would weaken the trend.
The nearest floor, 10.8% below — buyers have tended to step in here.
The nearest ceiling, 13.1% above — a clean break opens room to run.
A major ceiling 24.6% above — clearing it would confirm fresh momentum.
Key RLMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RLMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.41 | Sell | $6.44 | Sell |
| MA 10 | $6.53 | Sell | $6.48 | Sell |
| MA 20 | $6.57 | Sell | $6.55 | Sell |
| MA 50 | $6.84 | Sell | $6.61 | Sell |
| MA 100 | $6.48 | Sell | $6.21 | Buy |
| MA 200 | $4.96 | Buy | $5.16 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.82 | Neutral |
| Stoch RSI (14) | 23.66 | Neutral |
| CCI (20) | -62.82 | Neutral |
| Williams %R (14) | -81.43 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -5.32 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 18.57 | Buy |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | -0.20 | Sell |
| Ultimate (7,14,28) | 31.77 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 6.41 | Buy |
| ADX (14) | 9.84 | Neutral |
| ATR (14) | 0.16 | Info |
The 30-day technical picture is bullish in sentiment, with RSI14 listed at 50, while the near-term moving averages show $7.03 for the SMA50 and $4.58 for the SMA200. Near-term support is at $5.72 and resistance at $7.86, signaling a defined range around the current price. The 30-day price range is $5.36 to $8.45, and the asset exhibits notable near-term volatility at an annualized level of 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.55 | $6.41 | $9.60 | 0% | Neutral | |
| $6.85 | $8.65 | $11.58 | +35% | Bullish | |
| $8.44 | $10.98 | $15.28 | +71% | Bullish | |
| $9.23 | $12.30 | $17.65 | +92% | Bullish | |
| $10.58 | $14.43 | $21.23 | +125% | Bullish | |
| $13.52 | $18.79 | $28.28 | +193% | Bullish | |
| $16.20 | $22.95 | $35.23 | +258% | Bullish | |
| $19.53 | $28.16 | $44.00 | +339% | Bullish | |
| $21.51 | $31.53 | $50.10 | +392% | Bullish | |
| $21.71 | $32.33 | $52.16 | +404% | Bullish | |
| $39.47 | $63.18 | $108.71 | +886% | Bullish | |
| $71.62 | $129.96 | $245.48 | +19.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.55 | $6.41 | $7.92 | +0.00% |
| August 2026 | $5.82 | $6.88 | $8.36 | +7.37% |
| September 2026 | $5.81 | $6.92 | $8.50 | +0.53% |
| October 2026 | $5.98 | $7.17 | $8.90 | +3.60% |
| November 2026 | $6.26 | $7.55 | $9.45 | +5.29% |
| December 2026 | $6.29 | $7.61 | $9.60 | +0.87% |
Click any year to see its month-by-month RLMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Relmada Therapeutics, Inc.'s 2026 outlook centres on $6.41, within a $3.55 to $9.60 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, RLMD could reach as high as $11.58, with a base case around $8.65 and support toward $6.85 — roughly +35% from $6.41. Buyers look set to stay in control over this stretch.
Expect RLMD to range from $8.44 to $15.28 through 2028. The $10.98 average target implies a +71% move from current prices. That is up +27% on the projected 2027 average. Momentum favours further upside here.
The RLMD price prediction for 2029 points to an average of $12.30 (low $9.23, high $17.65) — a potential gain of +92% on today's $6.41. Buyers look set to stay in control over this stretch.
In 2030, RLMD is projected to trade between $10.58 and $21.23, averaging $14.43 — a potential gain of +125% from today's $6.41. That is up +17% on the projected 2029 average. Momentum favours further upside here.
Relmada Therapeutics, Inc.'s 2031 outlook centres on $18.79, within a $13.52 to $28.28 range. That is up +30% on the projected 2030 average. That marks a +193% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, RLMD could reach as high as $35.23, with a base case around $22.95 and support toward $16.20 — roughly +258% from $6.41. Momentum favours further upside here.
Expect RLMD to range from $19.53 to $44.00 through 2033. The $28.16 average target implies a +339% move from current prices. That is up +23% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The RLMD price prediction for 2034 points to an average of $31.53 (low $21.51, high $50.10) — a potential gain of +392% on today's $6.41. Momentum favours further upside here.
In 2035, RLMD is projected to trade between $21.71 and $52.16, averaging $32.33 — a potential gain of +404% from today's $6.41. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Relmada Therapeutics, Inc.'s 2040 outlook centres on $63.18, within a $39.47 to $108.71 range. That is up +95% on the projected 2035 average. That marks a +886% change versus current levels. Momentum favours further upside here.
By 2050, RLMD could reach as high as $245.48, with a base case around $129.96 and support toward $71.62 — roughly +19.3x from $6.41. Buyers look set to stay in control over this stretch.
Investing $1,000 in RLMD today (≈ 156.00624 RLMD) could be worth
$20,273.99
+$19,273.99 (+1927%) by 2050 · US Dollar
Based on the average projected RLMD price of $129.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RLMDwould be worth at today's price.
$1,000 invested in RLMD on Jul 10, 2025 (≈ 1,492.537276 RLMD) would be worth
$9,567.16
+$8,567.16 (+856.7%) today · 9.57× · US Dollar
Based on a RLMD entry price of $0.67 vs. today's $6.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.28 | $1,020.7 | +2.1% |
| 1 month ago | $6.38 | $1,004.7 | +0.5% |
| 3 months ago | $7.29 | $879.29 | -12.1% |
| 6 months ago | $4.11 | $1,559.61 | +56.0% |
| 1 year ago | $0.67 | $9,567.16 | +856.7% |
| All time (5.0y) ago | $33.49 | $191.4 | -80.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RLMD forecast.
Our base-case forecast reaches $13.00 around 2030.
Implied market cap at $13.00: $1.36B
The multi-year forecast depicts a clear upward trajectory. In 2026, the avg price is $6.73 with an average path rising to 2030 at $14.71 (ROI 118.5%) and bullish sentiment continuing thereafter. By 2040, the forecast projects an average of $62.26 with ROI of 825.2% and continued bullish sentiment.
By 2050, the forecast shows an average of $119.42 with ROI of 1674.4% and sustained bullish sentiment, indicating substantial long-term upside relative to today’s price. These are estimates, not guarantees, and actual results may vary.
Tap a question to reveal the answer.
Avg $14.71, min $10.39, max $22.56, ROI 118.5%, sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward, with 2027 avg $9.00, 2028 avg $11.32, 2029 avg $12.13, and 2030 avg $14.71; ROI figures include 33.7%, 68.1%, 80.3%, and 118.5% respectively. These are estimates, not guarantees.
Yes. The forecast lists 2033 max $47.69 and 2034 max $52.33, meaning a price above $50 could occur by 2034 according to the projections.
Current price is $6.73 and market cap is $705.91M.
The 30-day range is $5.36 to $8.45.
Relmada Therapeutics, Inc. Community Discussion
0Share your Relmada Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.